510(k) · Cleared
ClearedBinaxnow G6PD Test
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Binax, Inc. · JBF Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening
Cleared on Oct 23, 2008 as substantially equivalent to K933934 (Sigma Diagnostics, Inc., 1995) after a 295-day review. Its family tree reaches back 1 generation to 1995. 1 later device descends from it.
- Decided
- Oct 23, 2008
- Review
- 295 days
- Class
- Class II
- Product code
- JBF
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K933934 (1995). 1 later device descends from it, 1 citing it directly.
Most influential descendants
Showing 1 of 1 · See all- K161364BinaxNOW G6PD TestAlere Scarborough, Inc. · 2016 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K933934 | Glucose-6-Phosphate Dehydrogenase Deficiency Screening Test Kit NO. 202-a | Sigma Diagnostics, Inc. | 1995 | — |
| 0 (this device) | K080003 | Binaxnow G6PD Test | Binax, Inc. | 2008 | — |
| +1 | K161364 | BinaxNOW G6PD Test | Alere Scarborough, Inc. | 2016 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2016 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JBF? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new JBF device
- #1 K201049 Finder G6PDscore 4.0 · 1 generation · no Class I recall
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K933934 | Glucose-6-Phosphate Dehydrogenase Deficiency Screening Test Kit NO. 202-aSummary page 1…hate Dehydrogenase (Erythrocytic), Screening (per 21 CFR 864.7360) PREDICATE DEVICE Trinity Biotech Glucose-6-Phosphate Dehydrogenase (G-6-PDH) Deficiency reagent set, #K933934. DEVICE DESCRIPTION The BinaxNOW® G6PD test device consists of a lateral flow test strip comprised of a white sample pad and a r… | 1995 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K161364 | BinaxNOW G6PD Test | 2016 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- Of its descendants, K161364 (Alere Scarborough, Inc., 2016) has gone furthest, with 0 descendants of its own.
How does its category compare?
All JBF devicesJBF Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening: FDA decisions, review times, recalls and adverse event reports over 20 years. 2008, this device’s year, is highlighted.
FDA decisions per year · JBF
1in 2022
2026 to Oct 25, outlined.
Median 510(k) review, days · JBF
Too few JBF 510(k)s in any year since 2007 to give a median.
Recalls per year · JBF
No recall names JBF since 2007.
Adverse event reports per year · JBF
4in 2023
MAUDE reports naming product code JBF, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 1 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 1 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 1 |
| 2020 | 0 | — | 0 | 1 |
| 2021 | 0 | — | 0 | 1 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 4 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The BinaxNOW® G6PD (Glucose-6-Phosphate Dehydrogenase) Test is an in vitro enzyme chromatographic test for the qualitative detection of G6PD enzyme activity in human venous whole blood, collected in heparin or ethylenediaminetetraacetic acid (EDTA). The BinaxNOW® G6PD Test is a visual screening test used for differentiating normal from deficient G6PD activity levels in whole blood and is intended to aid in the identification of people with G6PD deficiency. Samples which generate deficient results should be assayed using a quantitative G6PD test method to verify the deficiency.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K080003 · printed Nov 5, 2026
Cite this page
510(k) Report. “K080003: Binaxnow G6PD Test.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K080003
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026